Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evolus (EOLS) Cash & Current Investments (2018 - 2026)

Evolus filings provide 9 years of Cash & Current Investments readings, the most recent being $49.8 million for Q1 2026.

  • On a quarterly basis, Cash & Current Investments fell 26.66% to $49.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $49.8 million, a 26.66% decrease, with the full-year FY2025 number at $53.8 million, down 38.1% from a year prior.
  • Cash & Current Investments hit $49.8 million in Q1 2026 for Evolus, down from $53.8 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $106.7 million in Q1 2022 to a low of $31.5 million in Q1 2023.
  • Median Cash & Current Investments over the past 5 years was $62.8 million (2023), compared with a mean of $66.2 million.
  • Biggest five-year swings in Cash & Current Investments: soared 381.13% in 2022 and later plummeted 70.5% in 2023.
  • Evolus' Cash & Current Investments stood at $53.9 million in 2022, then grew by 16.53% to $62.8 million in 2023, then skyrocketed by 38.37% to $87.0 million in 2024, then crashed by 38.1% to $53.8 million in 2025, then fell by 7.49% to $49.8 million in 2026.
  • The last three reported values for Cash & Current Investments were $49.8 million (Q1 2026), $53.8 million (Q4 2025), and $43.5 million (Q3 2025) per Business Quant data.